In type 2 diabetes with CVD and kidney disease, empagliflozin reduced mortality and hospitalization

Ann Intern Med. 2018 May 15;168(10):JC52. doi: 10.7326/ACPJC-2018-168-10-052.
No abstract available

Publication types

  • Comment

MeSH terms

  • Benzhydryl Compounds
  • Cardiovascular Diseases*
  • Diabetes Mellitus, Type 2*
  • Glucosides
  • Hospitalization
  • Humans
  • Renal Insufficiency, Chronic*

Substances

  • Benzhydryl Compounds
  • Glucosides
  • empagliflozin